Scarica l'app Stockscreener
0.1705
8.82%
-0.0165
Dopo l'orario di chiusura:
.18
0.0095
+5.57%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Theriva Biologics Inc Borsa (TOVX) Ultime notizie
Theriva Biologics, Inc. Estimates – AMEX:TOVX - TradingView
Theriva Biologics Proposes 500 Million Share Increase and Warrant Ratification for November 18 Meeting - Kalkine Media
Stockholders face another vote on $0.54 warrants at Theriva Biologics (TOVX). - Stock Titan
Theriva Biologics, Inc. (TOVX) Stock Price & News - Syfe
Form PRE 14A Theriva Biologics Inc For: 9 October By Investing.com - Investing.com Nigeria
Theriva™ Biologics anuncia la publicación en Nature Medicine de los resultados del ensayo clínico de Fase 2b VIRAGE con VCN-01 en el cáncer de páncreas metastásico - GlobeNewswire Inc.
Theriva publishes VCN-01 pancreatic cancer trial data in journal By Investing.com - Investing.com Canada
Theriva™ Biologics Announces Publication of the Results from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer Published in Nature Medicine - Yahoo! Finance Canada
Theriva™ Biologics Announces Publication of the Results - GlobeNewswire
Theriva Biologics Inc. (TOVX) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Theriva Biologics Inc. (TOVX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Theriva Biologics Inc. (TOVX) Peer Comparison – Compare with Others - Value Research
Theriva Biologics Inc. (TOVX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Theriva (TOVX) Earnings Report: The Available Figures Are Largely Near Expectations; Post-Report: The Stock Finishes Near Unchanged on the DayConsensus Beat Rate - vinanet.vn
Theriva (TOVX) Earnings Report: The Available Figures Are Largely Near Expectations; Post-Report: The Stock Finishes Near Unchanged on the DaySaaS Earnings Trends - careplusvn.com
Theriva Biologics(TOVX) Stock Options Chain | Quotes & News - Moomoo
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportRounding Bottom - vinanet.vn
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportPCR Divergence - dars.gov.et
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportVolatility Skew - careplusvn.com
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportStock News - dars.gov.et
Theriva Biologics (TOVX) Edges Down 0.87% to $0.23, Holding Above SupportFactor Crowding - dars.gov.et
Theriva Biologics (TOVX) Holds at $0.23 as Micro-Cap Biotech Tests Key Support ZoneQuality Factor - vinanet.vn
Theriva Biologics (TOVX) Holds at $0.23 as Micro-Cap Biotech Tests Key Support ZoneUp Down Volume - https://www.siam.in/
Theriva Biologics (TOVX) Dips 4.17% to $0.23 as Micro-Cap Biotech Holds Above $0.22 SupportSentiment Divergence - vinanet.vn
Theriva Biologics (TOVX) Dips 4.17% to $0.23 as Micro-Cap Biotech Holds Above $0.22 SupportBuy Signal Reports - https://www.dars.gov.et/
Maxim Group Maintains Theriva Biologics(TOVX.US) With Buy Rating, Maintains Target Price $1 - Moomoo
Theriva Biologics Releases Q2 2026 Financial Results - AlphaStreet
Form 8K Theriva Biologics Inc For: 11 August By Investing.com - Investing.com Nigeria
Theriva Biologics, Inc. 2026: Revenue ($3.35M), Net income ($3.22M), EPS ($0.07) — 10-Q Summary - TradingView
Form 8K Theriva Biologics Inc For: 11 August By Investing.com - Investing.com Canada
Theriva Biologics reports $3.2 million Q2 loss and VCN-01 dosing progress - Quiver Quantitative
Theriva Biologics reports Q2 2026 results; $11.3M cash, net loss $3.2M for quarter - TradingView
Theriva Biologics (NYSE American: TOVX) narrows Q2 loss, advances VCN-01 trial - Stock Titan
Theriva Biologics: Q2 Earnings Snapshot - marketscreener.com
Theriva Biologics: Q2 Earnings Snapshot - AOL.com
Theriva Biologics: Q2 Earnings Snapshot - KTVB
Theriva Biologics 2Q Loss/Shr 7c >TOVX - Moomoo
BRIEF-Theriva Biologics Q2 Net Income USD -3.217 Million - TradingView
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - GlobeNewswire
Theriva Biologics: Q2 Earnings Snapshot - finance.yahoo.com
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - The Manila Times
Theriva Biologics Doses First Patients in VIRAGE2 Phase 2a Trial of Repeated VCN-01 Dosing in Metastatic Pancreatic Cancer - Quiver Quantitative
Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - Yahoo Finance
Theriva Biologics Inc (TOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Theriva doses first patient in VCN-01 pancreatic cancer trial By Investing.com - Investing.com South Africa
Theriva Biologics Doses First Patient in VIRAGE2 Phase 2a Trial to Refine VCN-01 Therapy for Metastatic Pancreatic Cancer – Minichart - Minichart
Form 8K Theriva Biologics Inc For: 6 August By Investing.com - Investing.com Nigeria
Form 8K Theriva Biologics Inc For: 6 August By Investing.com - Investing.com South Africa
Theriva doses first patient in VCN-01 pancreatic cancer trial By Investing.com - Investing.com Nigeria
Theriva Biologics (NYSE American: TOVX) starts VIRAGE2 Phase 2a trial in PDAC - Stock Titan
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):